Kilimanjaro Climb to Fight Cancer

July 2019

Let’s Take Cancer Research to the Top

After a successful summit of Mt. Everest, the highest mountain in the world, Luke Timmerman has set his sights on Mt. Kilimanjaro, the highest peak in Africa. Formed by biotech executives and investors from around the country, Team Kilimanjaro will travel to Tanzania in July 2019.

Team Kilimanjaro climbers are committed to raising $50,000 or more to support cancer research at Fred Hutch. Luke’s Mt. Everest Climb to Fight Cancer raised $340,000 for Fred Hutch.

This year, the goal is $1.3 million.

Fundraising total as of June 12, 2019: $1,313,477

DONATE NOW

The Cancer Summit Series

Seattle Cancer Summit, May 10

Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support research at Fred Hutch.

1 pm-6 pm, May 10, Fred Hutch, Pelton Auditorium, Seattle

1 pm Registration

1:30 pm Welcome Remarks. Kelly O’Brien & Luke Timmerman

1:35 pm. Opening keynote. (30 minutes)

  • Harmit Malik, investigator, HHMI; full member, Basic Sciences Division, Fred Hutch

2:05 pm New Ideas for Cancer (10 minutes each)

  • Clayton Knox, chief operating officer, Mavupharma
  • Carla Grandori, CEO, SEngine Precision Medicine
  • Sam Blackman, founder and chief medical officer, Day One Therapeutics
  • Heidi Hagen, co-founder and chief strategy officer, Vineti
  • Jonathan Drachman, CEO, Neoleukin Therapeutics
  • Julie Eastland, CFO and chief business officer, Rainier Therapeutics

3:05 pm Cancer Investment. What are the Big Stories Hardly Anyone’s Talking About?

  • Steve Harr, co-founder and CEO, Sana Biotechnology (moderator)
  • Peter Thompson, private equity partner, OrbiMed; co-founder, Silverback Therapeutics
  • Tom Daniel, venture partner, ARCH Venture Partners
  • Mitchell Gold, executive chairman and CEO, Alpine Immune Sciences

3:25 pm. Venture Financing Models. When to Go Big? When is Small Beautiful?

  • Racquel Bracken, vice president, Venrock
  • Thong Le, CEO, Accelerator Life Science Partners
  • Charlotte Hubbert, partner, Gates Foundation Venture Capital
  • Bob More, partner, Alta Partners (moderator)

3:45 pm NETWORKING BREAK

4:10 pm New Information, New Insights for Cancer

  • Chad Robins, co-founder and CEO, Adaptive Biotechnologies
  • Brad Gray, CEO, NanoString Technologies
  • Iva Toudjarska, SVP, BRIDGEs Partnerships, North America and Newcos, Evotec (moderator)

4:40 pm The Cost for Patients

  • Veena Shankaran, co-director, Hutchinson Institute for Cancer Outcomes Research
  • Robin Yabroff, strategic director, economic burden of cancer, American Cancer Society

5:10 pm. Closing Conversation. The Future of Data Science in Cancer

  • Gary Gilliland, president and director, Fred Hutch
  • Matt McIlwain, chairman of the board of trustees, Fred Hutch
  • Natasha Hernday, SVP of corporate development, Seattle Genetics (moderator)

5:40 pm A Word on the Kilimanjaro Climb to Fight Cancer.

  • Luke Timmerman

5:45 pm NETWORKING

6 pm END

REGISTER NOW

Boston Cancer Summit, Apr. 16

Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support research at Fred Hutch.

1-6 pm, Apr. 16, Alexion Pharmaceuticals, 121 Seaport Blvd., Boston

1 pm Registration

1:30 pm Welcome Remarks. Alexion’s Rana Strellis & Luke Timmerman

1:35 pm Why I’m Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)

  • Uciane Scarlett, associate, Atlas Venture
  • Katrine Bosley, biotech entrepreneur
  • Praveen Tipirneni, CEO, Morphic Therapeutic
  • Deaidra Smith, director of portfolio communications, Alexion

1:40 pm New Ideas for Cancer Treatment (10 minute slide presentations)

  • Simba Gill, Evelo Biosciences (monoclonal microbials for cancer)
  • Karen Akinsanya, chief biomedical scientist, Schrodinger
  • Sanjiv Patel, Relay Therapeutics, (computational drug discovery)
  • Art Krieg, Checkmate Pharmaceuticals (CpG oligonucleotides)
  • Tariq Kassum, Obsidian Therapeutics (tunable T-cell therapies)
  • Leigh Zawel, Cullinan Oncology (portfolio of platforms & mechanisms)

2:50 pm Cancer Investment Landscape. Separating the Hype from the Reality

  • Elliott Sigal, venture partner, NEA
  • Phil Rowlands, head, oncology therapeutic area unit, Takeda
  • Doug Cole, managing partner, Flagship Pioneering (moderator)

3:20 pm BREAK

3:40 pm Where to Focus the Energy? A View From Pharma

  • Paul Biondi, SVP, business development and strategy, Bristol-Myers Squibb
  • John Reed, EVP, global head of R&D, Sanofi
  • Kate Haviland, Blueprint Medicines (moderator)

4 pm How to Make It Easier for Patients to Get Access to New Therapies?

  • Zoe Barry, CEO, ZappRx
  • Richa Wilson, Genentech/Roche, digital partnerships
  • Simon Kennedy, CEO, TriAxia Health (moderator)

4:30 pm What’s a Fair Way to Pay for All This?

  • Jeff Berkowitz, CEO, Real Endpoints
  • Leora Schiff, principal, Altius Strategy Consulting

5 pm Closing Conversation on the Future for Cancer Care

  • David Schenkein, executive chairman, Agios Pharmaceuticals; general partner GV
  • Mary Lynne Hedley, co-founder and president, Tesaro
  • Cindy Perettie, CEO, Foundation Medicine
  • Deb Palestrant, partner, 5AM Ventures (moderator)

5:30 pm A Word on the Kilimanjaro Climb to Fight Cancer.

  • Luke Timmerman

5:35 pm NETWORKING

6 pm END

REGISTER NOW

San Francisco Cancer Summit, Apr. 18

Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support research at Fred Hutch.

1-6 pm, Apr. 18, Biocom Bay Area, 1 Tower Place, South San Francisco

1 pm Registration

1:30 pm Welcome. JLABS’ Lesley Stolz & Luke Timmerman

1:35 pm Why I’m Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)

  • Lesley Stolz, head, JLABS Bay Area
  • Bill Newell, CEO, Sutro Biopharma
  • Ken Brunt, VP of customer operations, Veracyte
  • Julia Owens, CEO, Millendo Therapeutics

1:40 pm Why Genentech is Betting Big on Personalized T-cell therapies

  • Ira Mellman, vice president, research oncology, Genentech
  • Harlan Robins, member, Fred Hutch; program head, computational biology; co-founder, Adaptive Biotechnologies
  • Kristina Burow, managing director, ARCH Venture Partners (moderator)

2:00 pm New Ideas for Cancer Treatment (10 minutes each)

  • Carolyn Bertozzi, Anne T. and Robert M. Bass Professor of Chemistry at Stanford; Co-Founder, Palleon Pharmaceuticals (targeting glycan sensing checkpoints)
  • Omid Farokhzad, CEO, Seer (proteomics for early cancer detection)
  • Angie You, CEO, Amunix Pharmaceuticals (protein therapeutics)
  • Steve James, CEO, Pionyr Immunotherapeutics (antibodies for immune responses in tumor microenvironment)
  • Daniel Corey, founder and CSO, Cero Therapeutics (engineered cells to engulf and degrade tumors)
  • Alex Franzusoff, CEO, PACT Pharma
  • Ben Hindson, co-founder and CSO, 10X Genomics (insights from single-cell analysis)

3:10 pm The Future of Cancer Immunotherapy. T-cells, bispecifics, all of the above?

  • David Chang, co-founder and CEO, Allogene Therapeutics
  • Bassil Dahiyat, CEO, Xencor
  • Stanley Riddell, member, Fred Hutch; scientific director, Immunotherapy Integrated Research Center; co-founder, Juno Therapeutics
  • Julia Owens, CEO, Millendo Therapeutics (moderator)

3:30 pm BREAK

3:50 pm Beyond the Science: Regulatory, Commercial and Data Transformations Enabling the Cancer Revolution

  • Amy DuRoss, CEO, Vineti
  • Kristen Hege, Corporate VP, translational development, hematology/oncology, Celgene
  • Tim Moore, EVP, technical operations, Kite Pharma
  • Ashley Koegel, postdoctoral fellow, Wendell Lim laboratory, UCSF
  • Nina Kjellson, general partner, Canaan Partners (moderator)

4:30 pm What Will it Take for Molecular Diagnostics Reach Their Potential?

  • Bonnie Anderson, co-founder and CEO, Veracyte
  • Kevin Conroy, CEO, Exact Sciences
  • Lesley Stolz, JLABS Bay Area (moderator)

5 pm Closing Conversation on the Future for Cancer Care

  • Hal Barron, chief scientific officer and president of R&D, GSK
  • Larry Corey, past president of Fred Hutch, co-PI, HIV Vaccine Trials Network; co-founder, Juno Therapeutics
  • Racquel Bracken, vice president, Venrock (moderator)

5:30 pm A Word on the Kilimanjaro Climb to Fight Cancer.

  • Luke Timmerman

5:35 pm NETWORKING

6 pm END

REGISTER NOW

Kilimanjaro Climbing Team, July 17-28

Guides:

Summit Sponsor:

Machame Route Sponsor:

Peak Sponsors:

Base Camp Sponsors:

Trailhead Sponsors

Guide Service:

FAQs

Is the Climb to Fight Cancer/Fred Hutchinson Cancer Research Center a 501(c)(3) nonprofit institution and is my donation tax-deductible?

Yes. Climb to Fight Cancer is an event put on by Fred Hutch, a nonprofit organization incorporated in the state of Washington, that accepts donations from all 50 states. Our tax ID number is 23-7156071. All donations are tax-deductible to the extent allowed by law. The Fred Hutch IRS determination letter can be found in your participant center.

Will my donors receive tax receipts?

All donations made payable to and received by Climb to Fight Cancer/Fred Hutch will receive an acknowledgement for tax purposes. If a donation is not made directly to the Climb to Fight Cancer/Fred Hutch by the donor, Fred Hutch cannot provide a tax acknowledgement.

Donations received via check or cash will be acknowledged via mail no later than January 31, 2020.

How can someone donate to my climb?

The easiest way for someone to make a donation to your climb is via credit card directly on your fundraising page. Donors can also give via check (see question about personal checks), cash (see question about donating cash), donor advised funds, wire transfers, stock, and matching gifts. All gifts should indicate that they are for the Climb to Fight Cancer and should include the name of the climber to ensure proper recording to your fundraising page.

For instructions on electronic fund transfers/ACH, stock gifts, or for any questions, please email Cate Tambeaux at ctambeau@fredhutch.org.

Who should my donors make personal checks payable to?

Checks should be made payable to “Fred Hutch.” Include “Climb to Fight Cancer” and the name of the climber whom the donation should be applied to in the memo field. Donors should send checks to the address:

Fred Hutchinson Cancer Research Center
ATTN: Climb to Fight Cancer
1100 Fairview Ave. N., J5-200
Seattle, WA 98109

Fred Hutch will send a thank you and tax acknowledgement to the name and address appearing on the check.

What do I do if a donor gives me cash?

Please do not send cash through the mail. If you live in the Seattle area, please contact Cate Tambeaux at ctambeau@fredhutch.org to make arrangements to drop off the cash donation at Fred Hutch (823 Yale Ave N, Seattle, WA 98109). Otherwise please obtain a cashier check for the amount and send this to Fred Hutch along with the donor’s name and address so we can send a thank you and tax acknowledgement. Please do not write a personal check to cover the cash donation. If you write a check, we can only acknowledge you as the donor.

How long will it take for a donation to appear on my fundraising page?

Gift postings vary depending on the type of donation. All online donations will appear immediately. Donations made through other forms may experience delays in recording for a variety of reasons, including: mail delays, Fred Hutch staff availability, bank processing times, and company match distribution timing.

How are matching gifts credited toward my fundraising goal?

To submit a matching gift, simply ask your company’s human resources or matching gifts representative to submit the paperwork to Fred Hutch. Be sure to note the matching gift is for Climb to Fight Cancer. Once we receive the matching gift, we’ll post it to your fundraising page.

Please note: The time it takes to receive the actual gift can vary depending on your company. Some companies will send the money within a couple of weeks of your request, while others may take longer.

Matching gifts are an easy way to increase your fundraising. Be sure to encourage your donors to submit matching gift requests to leverage your fundraising.

What if someone outside of the United States wants to donate to my climb?

They can donate by credit card on your personal fundraising page and enter the amount in U.S. dollars. Please encourage any Canadian friends to donate online instead of by check.

Further questions? Please reach out to Cate Tambeaux at ctambeau@fredhutch.org or 206.667.2840.

GIVE NOW

Related Videos:

GIVE NOW